+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Devic's Syndrome Treatment Market - Global Forecast 2026-2032- Product Image
Devic's Syndrome Treatment Market - Global Forecast 2026-2032- Product Image
New

Devic's Syndrome Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 181 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5977777
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Devic’s Syndrome Treatment Market is defined by increasing clinical complexity, advances in therapy, and heightened expectations from care providers, payers, and commercial players. Industry leaders require actionable and current insights to adapt strategies and drive sustainable growth in this evolving field.

Market Snapshot: Devic’s Syndrome Treatment Market

The Devic’s Syndrome Treatment Market grew from USD 230.71 million in 2025 to USD 241.32 million in 2026. It is projected to expand at a CAGR of 4.83%, reaching USD 321.02 million by 2032. This steady growth reflects rising demand for advanced biologics, refined diagnostic tools, and expanded integration across care settings, with supply chains adjusting to multidimensional trade and distribution challenges.

Scope & Segmentation

This report offers a detailed analysis to inform strategic decision-making across:

  • Treatment Types: Corticosteroids (intravenous, oral), immunosuppressants (azathioprine, mycophenolate mofetil), monoclonal antibodies (eculizumab, inebilizumab), plasma exchange (automated, manual), supportive therapies (pain management, physiotherapy).
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
  • Care Settings: Hospitals, specialty clinics, home healthcare.
  • Regions: Americas, Europe, Middle East & Africa, Asia-Pacific—each presenting distinctive reimbursement policies, regulatory frameworks, and infrastructure realities.

Innovative technologies such as telemedicine, digital adherence tools, remote monitoring, and real-world evidence data capture are also assessed for their influence on access and operational delivery across these market segments.

Key Takeaways

  • Clinical care is shaped by heterogenous disease presentation and the ongoing evolution of diagnostic and therapeutic processes, demanding integrated, patient-centric pathways.
  • Emerging biologics and advanced protocols are altering standard algorithms, with variability in adoption stemming from differences in payer policies and provider infrastructure.
  • Supply chain resilience is increasingly vital due to tariff adjustments and shifting trade policies, prompting diversification of supplier networks and regional manufacturing strategies.
  • Distribution channel choice dictates delivery models, with hospital pharmacies playing a central role in managing infusion capacity and monitoring, complemented by online and retail pharmacy reach for maintenance therapies.
  • Regional policy diversity and infrastructure drive differences in therapy adoption, highlighting the importance of local adaptation and scenario planning for sustainable implementation.
  • Strategic partnerships between therapy developers, specialty distributors, and clinical service providers enhance access, operational efficiency, and regulatory compliance.

Tariff Impact

Tariff-related trade changes have added complexity to procurement and supply chain strategies, impacting cost structures from manufacturing through to distribution. Stakeholders are responding with more flexible sourcing, inventory optimization, and local packaging to maintain cost transparency and supply continuity. Service shifts towards point-of-care settings, including expanded home delivery and increased use of hospital pharmacies, are mitigating operational risks linked to tariff fluctuations, preserving both patient access and institutional budgets.

Methodology & Data Sources

Findings are grounded in structured interviews with clinicians, pharmacy directors, and operations leaders, supported by consultations with supply chain experts and secondary research from peer-reviewed literature and regulatory standards. Triangulation across sources, thematic coding, and scenario analysis underpin all insights. Measures were taken to ensure balanced input and neutral, practitioner-oriented recommendations.

Why This Report Matters

  • Informs executive decision-makers seeking to align clinical advancement, operational agility, and payer expectations in a variable marketplace.
  • Supports robust scenario planning by clarifying the interplay of regulatory shifts, new therapies, and distribution channels in diverse regions.
  • Enables development of sustainable strategies through a transparent view of trends, risks, and actionable opportunities across the devic’s syndrome treatment value chain.

Conclusion

Strategic success in the Devic’s Syndrome Treatment Market depends on integrating clinical, operational, and policy priorities. Adapting to evolving therapies, supply dynamics, and local realities will enable stakeholders to enhance patient outcomes and build resilient, scalable care pathways.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Devic's Syndrome Treatment Market, by Treatment Type
8.1. Corticosteroids
8.1.1. Intravenous
8.1.2. Oral
8.2. Immunosuppressants
8.2.1. Azathioprine
8.2.2. Mycophenolate Mofetil
8.3. Monoclonal Antibodies
8.3.1. Eculizumab
8.3.2. Inebilizumab
8.4. Plasma Exchange
8.4.1. Automated
8.4.2. Manual
8.5. Supportive Therapy
8.5.1. Pain Management
8.5.2. Physiotherapy
9. Devic's Syndrome Treatment Market, by Distribution Channel
9.1. Hospital Pharmacies
9.2. Online Pharmacies
9.3. Retail Pharmacies
10. Devic's Syndrome Treatment Market, by End User
10.1. Home Healthcare
10.2. Hospitals
10.3. Specialty Clinics
11. Devic's Syndrome Treatment Market, by Region
11.1. Americas
11.1.1. North America
11.1.2. Latin America
11.2. Europe, Middle East & Africa
11.2.1. Europe
11.2.2. Middle East
11.2.3. Africa
11.3. Asia-Pacific
12. Devic's Syndrome Treatment Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Devic's Syndrome Treatment Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. United States Devic's Syndrome Treatment Market
15. China Devic's Syndrome Treatment Market
16. Competitive Landscape
16.1. Market Concentration Analysis, 2025
16.1.1. Concentration Ratio (CR)
16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025
16.5. Alexion Pharmaceuticals Inc.
16.6. Alkem Laboratories Ltd.
16.7. Bio-Thera Solutions
16.8. Chugai Pharmaceutical Co., Ltd.
16.9. F. Hoffmann-La Roche Ltd.
16.10. Fresenius Kabi AG
16.11. Genentech Inc.
16.12. Horizon Therapeutics PLC
16.13. Lupin Ltd.
16.14. Mitsubishi Tanabe Pharma Corporation
16.15. Novartis AG
16.16. Pfizer Inc.
16.17. RemeGen Ltd
16.18. Sagent Pharmaceuticals Inc.
16.19. Sanofi S.A.
16.20. Teva Pharmaceutical Industries Ltd.
16.21. Zydus Pharmaceuticals Inc.
List of Figures
FIGURE 1. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 11. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 112. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 114. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 115. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 116. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 117. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. EUROPE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 130. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 131. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 132. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 133. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 134. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 135. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 149. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 150. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 151. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 152. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 153. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 154. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. ASEAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. GCC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. GCC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 158. GCC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 159. GCC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 160. GCC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 161. GCC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 162. GCC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 163. GCC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. GCC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. BRICS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. BRICS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 176. BRICS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 177. BRICS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 178. BRICS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 179. BRICS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 180. BRICS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 181. BRICS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. BRICS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. G7 DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. G7 DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 185. G7 DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 186. G7 DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 187. G7 DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 188. G7 DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 189. G7 DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 190. G7 DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. G7 DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. NATO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. NATO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 194. NATO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 195. NATO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 196. NATO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 197. NATO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 198. NATO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 199. NATO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. NATO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 213. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 214. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 215. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
TABLE 216. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2032 (USD MILLION)
TABLE 217. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
TABLE 218. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Devic's Syndrome Treatment market report include:
  • Alexion Pharmaceuticals Inc.
  • Alkem Laboratories Ltd.
  • Bio-Thera Solutions
  • Chugai Pharmaceutical Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Genentech Inc.
  • Horizon Therapeutics PLC
  • Lupin Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Pfizer Inc.
  • RemeGen Ltd
  • Sagent Pharmaceuticals Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals Inc.

Table Information

Report AttributeDetails
No. of Pages181
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 241.32 Million
Forecasted Market Value ( USD ) by 2032 $ 321.02 Million
Compound Annual Growth Rate4.8%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2025 - Product Image

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Neuromyelitis Optica Spectrum Disorder (NMOSD) - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Guillain-Barre Syndrome Market - Global Forecast 2026-2032 - Product Image

Guillain-Barre Syndrome Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Chronic Fatigue Syndrome Treatment Market - Global Forecast 2026-2032 - Product Image

Chronic Fatigue Syndrome Treatment Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Guillain-Barre Syndrome Drugs Market Report 2025 - Product Image

Guillain-Barre Syndrome Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Neuromyelitis Optica Drug Market

Neuromyelitis Optica (NMO) is a rare autoimmune disorder of the central nervous system (CNS) that affects the optic nerves and spinal cord. It is characterized by recurrent episodes of optic neuritis and transverse myelitis, which can lead to permanent vision loss and paralysis. Treatment of NMO is focused on reducing inflammation and preventing further damage to the CNS. Drugs used to treat NMO include corticosteroids, immunosuppressants, and monoclonal antibodies. Corticosteroids are used to reduce inflammation and prevent further damage to the CNS. Immunosuppressants are used to reduce the activity of the immune system and prevent further attacks. Monoclonal antibodies are used to target specific molecules involved in the autoimmune response. The NMO drug market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of NMO and the development of new treatments. Companies in the NMO drug market include Biogen, Alexion Pharmaceuticals, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.